# BioAtla, Inc. (BCAB) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BCAB
## Company Profile
- Ticker: BCAB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 3.5 USD
- Market cap: 5848948.779999999 USD
- Last updated: 2026-08-11
## Business Overview
### Conditionally Active Biologics
BioAtla develops antibodies engineered to bind preferentially under conditions found in the tumor microenvironment. The CAB platform uses factors such as acidic pH to reduce target binding in normal tissue and potentially limit on-target, off-tumor toxicity.
### BA3182
BA3182 is a conditionally active EpCAM and CD3 bispecific T-cell engager in Phase 1 development for advanced adenocarcinomas. Both binding arms are designed to activate preferentially within tumors.
### Antibody-Drug Conjugates
The clinical ADC portfolio includes ozuriftamab vedotin against ROR2 and mecbotamab vedotin against AXL. Programs have been studied in oropharyngeal cancer, sarcoma and KRAS-mutant lung cancer.
### Broader CAB Pipeline
Evalstotug is a conditionally active CTLA-4 antibody, while preclinical assets target Nectin-4, B7H4, B7H3, EGFR and Trop2. BioAtla is evaluating strategic transactions and may alter the pace or scope of these programs while preserving capital.
## Why The Stock Is Moving

As of Aug 11, 2026, BCAB closed up 0.86% at $3.50. No new same-company headline was identified in the current news window.

## Future Catalysts

- BioAtla’s catalysts are conditional-activation antibodies and any oncology update that shows the platform can still differentiate. The company remains data-sensitive because the platform story is not yet fully proven.

## Recent News
- 2026-03-31 20:06 EST — [BioAtla Announces Share Consolidation](https://biopharmsignal.com/news/BCAB/bioatla-announces-share-consolidation-87cc80c0) — Source: BioAtla, Inc.
- 2026-03-31 20:05 EST — [BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/BCAB/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-12e923ba) — Source: BioAtla, Inc.
- 2026-03-02 12:30 EST — [BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets](https://biopharmsignal.com/news/BCAB/bioatla-announces-formal-process-to-evaluate-strategic-options-to-monetize-asset-845454d9) — Source: BioAtla, Inc.
- 2025-12-31 12:00 EST — [BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)](https://biopharmsignal.com/news/BCAB/bioatla-and-gatc-health-announce-a-40-million-special-purpose-vehicle-spv-transa-3cc03299) — Source: BioAtla, Inc.
- 2025-11-21 05:25 EST — [BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing](https://biopharmsignal.com/news/BCAB/bioatla-enters-into-agreements-for-up-to-22-5-million-flexible-financing-33b8bcad) — Source: BioAtla, Inc.